Blocking Sirtuin

Columbia targets Sirtuin 1 in the prostate cancer that escapes treatment fastest

Neuroendocrine prostate cancer is a rare, hard and clinically difficult form of the disease, and a new Columbia study now ties it to one clear molecular lever: Sirtuin 1.